focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.
Cancer treatment specialist Antisoma firmed ¼p to 33¼p following an upbeat AGM. Broker KBC Peel Hunt has a target price of 70p. It expects to hear in the coming months early data from AS1411 for renal cancer, which could provide a further boost to sentiment. http://www.thisismoney.co.uk/markets/article.html?in_article_id=493475&in_page_id=3
Trikona Trinity Capital PLC announced the sale of its investment in Phoenix Mills Limited. On November 9, 2009, the Company sold its entire holding of 1,850,000 shares in Phoenix Mills into the market at INR170 per share, for settlement on November 12, 2009, giving a total net consideration of $ 6,637,000, equivalent to approximately GBP 3.9 million.
Biotechnology firm Antisoma is finishing 2009 in a strong position. Chief executive Glyn Edwards said two drugs were in pivotal phase III trials and the firm had significant cash resources. He added: "We are focused on completing key studies of our late-stage drugs and preparing for their commercialisation, while also continuing to explore opportunities to add new assets to our business." He added: "Before the end of this year, we expect the first data from our phase II trial of AS1411 in renal cancer and additional details of Novartis' plans for developing ASA404 in breast cancer. "We are moving forward with our plans to transition from a company focused on developing cancer drugs into one that can also successfully commercialise them. "While our principal focus is the completion of phase III trials on ASA404 and AS1413, we also continue to advance the earlier stage products in our portfolio and to explore opportunities to add new drugs to the pipeline." http://www.ibtimes.co.uk/articles/20091110/antisoma-finishing-year-in-strong-position.htm
Johan Goossens Acquires a 16.72% Stake in Cryo-Save Group NV-DJ Friday, 23 Oct 2009 02:40am EDT Dow Jones reported that Johan Goossens has acquired a 16.72% stake in Cryo-Save Group NV. The stake consists of 1,612,127 common shares. Mr. Goossens is co-founder and Non-Executive Director of the Company. 23,10.09 http://www.reuters.com/finance/stocks/keyDevelopments?symbol=CRYG.L
Cryo-Save shares trade on NYSE Euronext under the symbol “CRYO” and are denominated in Euros. After opening, the first market price was € 6.30 per share. Based on the total number of 9,639,191 shares the total market capitalization of the company at opening price was € 60,726,903. Marc Waeterschoot, Chief Executive, commented: “Being a Dutch company, with most of our business on the continent, a listing on NYSE Euronext’s European market should increase our visibility as well as liquidity and will therefore add value to the company and to the shareholders that have invested in us since our listing on AIM in London in 2007.” “We welcome Cryo-Save to NYSE Euronext’s European market, the largest and most liquid market in Europe. As a leading stem cell storage bank in Europe the company will gain unmatched access to investors in the eurozone.”, said Joost van der Does de Willebois, CEO of Euronext Amsterdam. http://www.euronext.com/news/press_release/press_release-1731-FR.html?docid=782603
Antisoma was given a boost last week on news that regulators on both sides of the pond have awarded orphan drug status to AS1411 for treating patients with acute myeloid leukaemia (AML). AS1411 belongs to a new group of drugs called aptamers, which are essentially short strands of DNA or RNA that fold into various three-dimensional structures that are able to target certain proteins on cells, including on tumours. Promising Phase II data - published at the 2008 ASH and 2009 ASCO meetings – showed that adding AS1411 to cytarabine substantially boosted response rates without significantly increasing side-effects in patients with relapsed or refractory AML, a disease in which the bone marrow makes abnormal and immature blood cells ultimately resulting in bone marrow failure. The UK drugmaker has now confirmed that the first of Phase IIb trials are expected to start early next year, and if results are positive it anticipates “rapid progress into a registration trial”. Speedy development and approval of the drug will be good news for patients given that this form of cancer has a very poor prognosis, with the potential to be fatal in just six-12 months. AS1411 has already been granted orphan drug status in the US and European Union for the treatment of renal cancer, in which initial Phase II data are expected before the end of the year, Antisoma said.
You're welcome.wish you all the best in your investments. Sp is moving up steadily and I don’t see anyone complaining about it. Some of us are sitting on a +500% gain (it was quoted at 15/16p. early this year). The way it goes up fast just seems to provoke some nervousness as there are some large expectations about the introduction on Euronext. The latest moves could be explained by this introduction. I suppose I don’t have to explain you what a tracker is. A lot of funds, who were not interested in Cryo-save, because of its listing on AIM, just will have to buy some Cryo-save, in order to comply with those biotechnology trackers they are mimicking. Other funds will add Cryo-save to their list of holdings just because they invest in biotech. Almost every major bank in Holland and Belgium has such a Biotech Fund on offer and Cryo-save will logically be part of those funds (at a certain percentage). Depending on its capitalization Cryo-save could also be promoted to some index. On AIM it might not be that important yet, but on Euronext/Amsterdam its capitalization will probably be as important as the capitalization of Fornix Biosciences. Cryo-save will join the ones like Crucell, Galapagos, Pharming, Fornix and AMT. So there could be (IMHO, there will be) a healthy interest for the shares. So the reason for the rise just might be that some third parties are already shopping at a cheaper price.posted by , Ambiorix1 .iii with thanks.
http://www.intermarketstocks.com/imsmembers/imsournews.php http://www.investegate.co.uk/Index.aspx http://www.shareprice.co.uk/ http://proactiveinvestors.co.uk/ http://www.miningweekly.com/page/breaking-news http://quote.barchart.com/texpert.asp?sym=KAZ.LS&code=BSTK http://www.iii.co.uk/investment/detail?code=cotn:CRYO.L&display=discussion hope this help for looking over news .this is but a fue
Arthur Millholland, former head of bankrupt Oilexco, is in talks with Premier Oil about buying back one of Oilexco's fields.
TORONTO (miningweekly.com) – Diamond giant De Beers has cancelled a planned four-week December shutdown at its Snap Lake underground mine, in Canada, because of improving market conditions, the company said on Tuesday. "This is a good news decision in response to some positive trends we are seeing in the market place," commented De Beers Canada CEO Jim Gowans. Besides Snap Lake, in the Northwest Territories, De Beers also owns and operates the Victor mine, in Ontario. After rough diamond demand plummeted in the fourth quarter of last year, the company cut employee and contractor jobs at Snap Lake and reduced output, first late in 2008 and then again in February this year, to trim costs and match market demand. However, there are increasing signs that demand for rough diamonds has begun to recover, particularly from Asian markets. Two weeks ago, Rio Tinto, which operates the Diavik mine, also in Canada's Northwest Territories, confirmed that the operation would not close in December, as had been previously planned, also citing improvements in demand and prices for rough diamonds. "While we are optimistic about the improvements we are seeing in the global industry, we will continue to make decisions carefully with a focus on the long term success for our new Canadian mines," Gowans said in a statement on Tuesday. Earlier this year, De Beers responded to the drop in demand by slashing production at its operations around the world,
http://www.iii.co.uk/investment/detail?code=cotn:OIL.L&display=discussion
Bank of America Merrill Lynch says the stock is worth 37p a share and reckons there is more to this one than its AS404 lung cancer treatment. Broker says: 'Our current valuation conservatively includes only phase III programs ASA404 in lung cancer & AS1413 in sAML plus net cash. Key developments related to Antisoma's early-stage pipeline that could translate to valuation upside in the longer term include the following: (1) Phase II headline data for AS1411 in renal cancer by YE09E; (2) phase IIb for ASA404 in breast cancer starts early 2010E; (3) phase IIb for AS1411 in relapsed/refractory AML starts early 2010E.'
Analysts favour Antisoma By Bryce Elder Published: September 18 2009 03:00 | Last updated: September 18 2009 03:00 Antisoma , the cancer drug developer, took on 5 per cent to 31½p after analysts said a value gap had opened up against its peer group. US oncology specialists have gained 89 per cent this year, compared with Antisoma's 38 per cent gain, PiperJaffray said. It saw the performance as anomalous given Antisoma's promising test data this year.
http://www.business-standard.com/india/news/cryo-save-expects-20-marketgujarat/370540/
Market talk that world diamond prices begun to recover in earnest is a buying signal for UK-quoted diamond miners. Debswana,a joint venture between the world's topdiamond producer DE Beers and the Botswana government,is reported as saying demand for the precious stones has improved'significantly' since the start of the year and prices began to recover last month. Investors should buy GEMD to get the greatest leverage from diamond price strength.broker RBC Capital Markets said earlier this month rough diamond prices defied the anticipated summer slowdown in diamond demand by remaining firm.Analyst Des Kilalea noted GEMD secured an average price of $1,588 per carat for the 9,600 carats it was selling in August's tender. This compared to an average of $1,308 per carat achieved by the £355 million cap firm in the first half of 2009. Shares in GEMD have recovered well since slumping to 137.8 in July.they have further to rise as it revives production levels.THE company will be promoted back to the FTSE 250 on Monday 21 September.
Investors with a penchant for biotechnology stocks should buy in to cancer drug specialist ASM there is scope for the stock to catch up with its peers ,VEC,BTG,BGC PSK,.Interim analysis of the phase 3 trial for its key ASA404 in non-small cell lung cancer is due early next year and the shares could rise ahead of this.The company is also expected to release data on a phase 2 trial for AS1411 for renal cancer in the second half of 09 .Earlier sale of fludarabine, a tablet for leukaemia, means ASM sits atop a cash pile of £67 million,enough to see it comfortably through until mid-2011 .ASA404, which has been licensed to swiss drug giant Novartis ,shows the potential to increase average life expectancy by five months.Even if this figure is knocked down during phase 3 there could still be sufficient clear water between it and current treatments to propel it to blockbuster sales, from which ASM would receive royalty payments.Of the current therapies,Roche's Avastin, which increases life expectancy by around two months,enjoys annual revenues of $4 billion per annum.The cash pile means ASMis less risky than much of the sector.
LONDON, Sept 14 (Reuters) - British cancer specialist Antisoma (ASM.L) should get "significant" revenues from 2012 as long as its two key products stay on track, taking it from being a drug developer to a speciality pharmaceutical company, according to its chief executive. "The big inflection point is product launches and that see saws you from being a company that generally consumes cash in operations to being one that is either profitable at that point or very soon after," Chief Executive Glyn Edwards told Reuters on Monday. The company said it could launch its blood cancer drug AS1413 in the U.S. in 2012, about the same time as partner Novartis (NOVN.VX) could launch its ASA404 drug as a lung cancer treatment. Edwards added that Antisoma had not had a takeover approach from Novartis. Earlier Antisoma said it had cash at the end of its financial year of 67.0 million pounds ($111.2 million).
Cryo - Save India, a part of Cryo-Save Group, Europe's largest adult stem cell storage bank, achieved a significant milestone with TUV Rheinland, Germany conferring the India operations an ISO 9001:2008 certification. TUV Rheinland, a leading quality management systems registrar from Germany, certified Cryo-Save India after examining the lab on various parameters. "The certification from TUV Rheinland serves to strengthen the processes and systems employed by Cryo-Save India, which include fully automated systems that ensure no human intervention in storage and retrieval process along with a unique dual storage process. This certification strengthens our core proposition of delivering global standards through our processes and systems" said Chandramouli, managing director, Cryo Save India. As part of the ISO 9001 process, TUV performed on-site assessments, examining the Cryo-Save India documented procedures and audited its overall operations. To determine continued compliance with ISO 9001:2008, TUV would conduct periodically scheduled audits at Cryo - Save India and examine and monitor its business operations. Quality Council of India, the authority in India for ISO related standards, too can conduct random audits to verify organization's compliance to declared practices. The ISO (International Organization for Standardization) standards are globally recognized as an effective framework for a quality management system (QMS). To be certified by ISO, Cryo S
3 September 2009, London, UK, and Cambridge, MA: Antisoma plc (LSE: ASM; USOTC: ATSMY) announces that Daniel Elger, VP Marketing & Communications, will present an overview of the Company's strategy, programmes and prospects at the Rodman & Renshaw 11th Annual Healthcare Conference in New York City, on Thursday, September 10th at 09:10 EDT/14:10 BST. A webcast of the presentation will be available on Antisoma's website at http://www.antisoma.com/asm/media/webcast/
Cryo-Save Group N.V. (AIM: CRYO, "Cryo-Save"), Europe's leading stem cell bank, plans to seek an additional listing on Euronext Amsterdam in the fourth quarter of the current financial year to complement the Group's shares being traded on AIM in London. Cryo-Save was admitted to trading on AIM on 6 November 2007. Cryo-Save intends to review the need to maintain the AIM listing early 2010. Cryo-Save expects to make further announcements with regards to the Euronext listing in due course. Marc Waeterschoot, Chief Executive, commented: "We are looking to become listed on Euronext in Amsterdam. Being a Dutch company, with most of our business on the continent, a local listing should increase our visibility as well as liquidity."